• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Encapsulation of the lipidated TLR7/8 agonist INI-4001 into ionic liposomes impacts H7 influenza antigen-specific immune responses.

作者信息

Mehradnia Fatemeh, Amin Hardik, Ferrini Maria E, Partlow Haley, Borgogna Timothy, Dachavaram Soma Shekar, T Ryter Kendal, Bazin Hélène G, Evans Jay T, Burkhart David J, DeBuysscher Blair, Abdelwahab Walid M

机构信息

Center for Translational Medicine-Adjuvant Research Team (CTM-ART), Missoula, MT, 59812, USA.

Department of Biomedical and Pharmaceutical Sciences, University of Montana, 32 Campus Drive, Missoula, MT, 59802, USA.

出版信息

Drug Deliv Transl Res. 2025 Jul 14. doi: 10.1007/s13346-025-01917-6.

DOI:10.1007/s13346-025-01917-6
PMID:40660065
Abstract
摘要

相似文献

1
Encapsulation of the lipidated TLR7/8 agonist INI-4001 into ionic liposomes impacts H7 influenza antigen-specific immune responses.将脂化的TLR7/8激动剂INI-4001包裹于离子脂质体中会影响H7流感抗原特异性免疫反应。
Drug Deliv Transl Res. 2025 Jul 14. doi: 10.1007/s13346-025-01917-6.
2
Co-Delivery of a Novel Lipidated TLR7/8 Agonist and Hemagglutinin-Based Influenza Antigen Using Silica Nanoparticles Promotes Enhanced Immune Responses.使用二氧化硅纳米颗粒共同递送新型脂化TLR7/8激动剂和基于血凝素的流感抗原可促进增强的免疫反应。
Pharmaceutics. 2024 Jan 13;16(1):107. doi: 10.3390/pharmaceutics16010107.
3
A novel cationic liposome-formulated toll like receptor (TLR) 7/8 agonist enhances the efficacy of a vaccine against fentanyl toxicity.一种新型阳离子脂质体配方的Toll样受体（TLR）7/8激动剂可增强抗芬太尼毒性疫苗的效力。
J Control Release. 2025 Aug 10;384:113901. doi: 10.1016/j.jconrel.2025.113901. Epub 2025 May 27.
4
A cationic liposome-formulated Toll Like Receptor (TLR)7/8 agonist enhances the efficacy of a vaccine against fentanyl toxicity.一种阳离子脂质体配方的Toll样受体（TLR）7/8激动剂可增强抗芬太尼毒性疫苗的效力。
bioRxiv. 2025 Jan 13:2025.01.08.631964. doi: 10.1101/2025.01.08.631964.
5
Co-encapsulation of synthetic lipidated TLR4 and TLR7/8 agonists in the liposomal bilayer results in a rapid, synergistic enhancement of vaccine-mediated humoral immunity.脂质体双层中合成的脂化 TLR4 和 TLR7/8 激动剂的共包封导致疫苗介导的体液免疫的快速协同增强。
J Control Release. 2019 Dec 10;315:186-196. doi: 10.1016/j.jconrel.2019.10.025. Epub 2019 Oct 22.
6
Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.合成的Toll样受体4（TLR4）和TLR7配体通过髓样分化因子88（MyD88）协同作用，在小鼠中诱导保护性抗病毒免疫。
J Virol. 2017 Sep 12;91(19). doi: 10.1128/JVI.01050-17. Print 2017 Oct 1.
7
Multiscale dynamic immunomodulation by a nanoemulsified Trojan-TLR7/8 adjuvant for robust protection against heterologous pandemic and endemic viruses.纳米乳化特洛伊木马-TLR7/8佐剂的多尺度动态免疫调节作用，用于对异源大流行和地方性病毒的强大保护。
Cell Mol Immunol. 2025 Jun 25. doi: 10.1038/s41423-025-01306-6.
8
A Novel Synthetic Dual Agonistic Liposomal TLR4/7 Adjuvant Promotes Broad Immune Responses in an Influenza Vaccine With Minimal Reactogenicity.一种新型合成双激动剂脂质体 TLR4/7 佐剂可增强流感疫苗的广泛免疫应答，且具有最小的致反应原性。
Front Immunol. 2020 Jun 19;11:1207. doi: 10.3389/fimmu.2020.01207. eCollection 2020.
9
TLR7-Adjuvanted Ionizable Lipid Nanoparticles for mRNA Vaccine Delivery.用于mRNA疫苗递送的TLR7佐剂可电离脂质纳米颗粒
AAPS J. 2025 Apr 25;27(4):80. doi: 10.1208/s12248-025-01073-2.
10
BBIQ, a pure TLR7 agonist, is an effective influenza vaccine adjuvant.BBIQ，一种纯 TLR7 激动剂，是一种有效的流感疫苗佐剂。
Hum Vaccin Immunother. 2020 Aug 2;16(8):1989-1996. doi: 10.1080/21645515.2019.1710409. Epub 2020 Apr 16.

本文引用的文献

1
ProLonged Liposomal Delivery of TLR7/8 Agonist for Enhanced Cancer Vaccine.用于增强癌症疫苗的TLR7/8激动剂的长效脂质体递送
Vaccines (Basel). 2023 Sep 19;11(9):1503. doi: 10.3390/vaccines11091503.
2
A Comparison of Cellular Uptake Mechanisms, Delivery Efficacy, and Intracellular Fate between Liposomes and Extracellular Vesicles.脂质体和细胞外囊泡的细胞摄取机制、递送效率和细胞内命运比较。
Adv Healthc Mater. 2023 Oct;12(25):e2300319. doi: 10.1002/adhm.202300319. Epub 2023 Jul 9.
3
Host Recovery from Respiratory Viral Infection.宿主从呼吸道病毒感染中恢复。
Annu Rev Immunol. 2023 Apr 26;41:277-300. doi: 10.1146/annurev-immunol-101921-040450. Epub 2023 Jan 30.
4
Towards the development of subunit vaccines against tuberculosis: The key role of adjuvant.朝着结核亚单位疫苗的开发：佐剂的关键作用。
Tuberculosis (Edinb). 2023 Mar;139:102307. doi: 10.1016/j.tube.2023.102307. Epub 2023 Jan 14.
5
Recent advancement, immune responses, and mechanism of action of various vaccines against intracellular bacterial infections.针对细胞内细菌感染的各类疫苗的最新进展、免疫反应及作用机制。
Life Sci. 2023 Feb 1;314:121332. doi: 10.1016/j.lfs.2022.121332. Epub 2022 Dec 28.
6
Exploring the impact of physicochemical properties of liposomal formulations on their in vivo fate.探索脂质体制剂的物理化学性质对其体内命运的影响。
Life Sci. 2022 Jul 1;300:120574. doi: 10.1016/j.lfs.2022.120574. Epub 2022 Apr 23.
7
Current view on novel vaccine technologies to combat human infectious diseases.当前对抗人类传染病新型疫苗技术的看法。
Appl Microbiol Biotechnol. 2022 Jan;106(1):25-56. doi: 10.1007/s00253-021-11713-0. Epub 2021 Dec 10.
8
Exploration of Pattern Recognition Receptor Agonists as Candidate Adjuvants.探索模式识别受体激动剂作为候选佐剂。
Front Cell Infect Microbiol. 2021 Oct 6;11:745016. doi: 10.3389/fcimb.2021.745016. eCollection 2021.
9
Overcoming scientific barriers in the transition from to non-animal batch testing of human and veterinary vaccines.克服从动物批次试验到人用和兽用疫苗的非动物批次试验转变中的科学障碍。
Expert Rev Vaccines. 2021 Oct;20(10):1221-1233. doi: 10.1080/14760584.2021.1977628. Epub 2021 Sep 22.
10
Platforms for Production of Protein-Based Vaccines: From Classical to Next-Generation Strategies.基于蛋白质的疫苗生产平台：从经典到下一代策略。
Biomolecules. 2021 Jul 21;11(8):1072. doi: 10.3390/biom11081072.